CN109825504A - It is a kind of inhibit circ_0001016 expression siRNA and its application - Google Patents
It is a kind of inhibit circ_0001016 expression siRNA and its application Download PDFInfo
- Publication number
- CN109825504A CN109825504A CN201910149634.6A CN201910149634A CN109825504A CN 109825504 A CN109825504 A CN 109825504A CN 201910149634 A CN201910149634 A CN 201910149634A CN 109825504 A CN109825504 A CN 109825504A
- Authority
- CN
- China
- Prior art keywords
- cancer
- nucleotide
- modification
- carcinoma
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000014509 gene expression Effects 0.000 title claims abstract description 8
- 108020004459 Small interfering RNA Proteins 0.000 title description 8
- 239000002773 nucleotide Substances 0.000 claims abstract description 27
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 27
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 12
- 230000000295 complement effect Effects 0.000 claims abstract description 9
- 108091028075 Circular RNA Proteins 0.000 claims abstract description 7
- 238000012986 modification Methods 0.000 claims description 21
- 230000004048 modification Effects 0.000 claims description 19
- 201000011510 cancer Diseases 0.000 claims description 7
- 201000009030 Carcinoma Diseases 0.000 claims description 6
- 108091028664 Ribonucleotide Proteins 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 239000002336 ribonucleotide Substances 0.000 claims description 6
- 125000002652 ribonucleotide group Chemical group 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 229910052785 arsenic Inorganic materials 0.000 claims description 4
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 claims description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 3
- 239000005547 deoxyribonucleotide Substances 0.000 claims description 3
- 125000002637 deoxyribonucleotide group Chemical group 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 206010000830 Acute leukaemia Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims description 2
- 208000022033 carcinoma of urethra Diseases 0.000 claims description 2
- 201000011603 cardia cancer Diseases 0.000 claims description 2
- 235000012000 cholesterol Nutrition 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 208000024207 chronic leukemia Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 210000000750 endocrine system Anatomy 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 201000010175 gallbladder cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000003956 middle ear cancer Diseases 0.000 claims description 2
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims description 2
- 201000001514 prostate carcinoma Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 210000001550 testis Anatomy 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical group OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 206010052178 Lymphocytic lymphoma Diseases 0.000 claims 1
- 241000218636 Thuja Species 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000003560 cancer drug Substances 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 208000026037 malignant tumor of neck Diseases 0.000 claims 1
- 201000005443 oral cavity cancer Diseases 0.000 claims 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 abstract description 3
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 3
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 14
- 230000030279 gene silencing Effects 0.000 description 12
- 239000002924 silencing RNA Substances 0.000 description 5
- PTLRDCMBXHILCL-UHFFFAOYSA-M sodium arsenite Chemical compound [Na+].[O-][As]=O PTLRDCMBXHILCL-UHFFFAOYSA-M 0.000 description 5
- 239000012096 transfection reagent Substances 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 3
- 238000011262 co‐therapy Methods 0.000 description 3
- 108091070501 miRNA Proteins 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 102100030088 ATP-dependent RNA helicase A Human genes 0.000 description 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N Arsenious Acid Chemical compound O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
- 102100029791 Double-stranded RNA-specific adenosine deaminase Human genes 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102100028818 Heterogeneous nuclear ribonucleoprotein L Human genes 0.000 description 1
- 101000864670 Homo sapiens ATP-dependent RNA helicase A Proteins 0.000 description 1
- 101000865408 Homo sapiens Double-stranded RNA-specific adenosine deaminase Proteins 0.000 description 1
- 101000839078 Homo sapiens Heterogeneous nuclear ribonucleoprotein L Proteins 0.000 description 1
- 101000633503 Homo sapiens Nuclear receptor subfamily 2 group E member 1 Proteins 0.000 description 1
- 101001100767 Homo sapiens Protein quaking Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 102100029534 Nuclear receptor subfamily 2 group E member 1 Human genes 0.000 description 1
- 239000012807 PCR reagent Substances 0.000 description 1
- 102100038669 Protein quaking Human genes 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 102000003890 RNA-binding protein FUS Human genes 0.000 description 1
- 108090000292 RNA-binding protein FUS Proteins 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 108010003165 Small Nuclear Ribonucleoproteins Proteins 0.000 description 1
- 102000004598 Small Nuclear Ribonucleoproteins Human genes 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 201000004962 larynx cancer Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 238000011022 operating instruction Methods 0.000 description 1
- 208000020717 oral cavity carcinoma Diseases 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000008684 selective degradation Effects 0.000 description 1
- 230000006807 siRNA silencing Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
Abstract
The invention discloses a kind of nucleotide of inhibition people circ_0001016 circular rna expression and its applications, it is characterized in that: the polynucleotide is incorporated into people's circ_0001016 circular rna, the sequence of the nucleotide is made of 18-23 continuous nucleotide sequence in AUUCUUUGCUUCGCACUGGUUCC sequence or complementary series, and especially it includes sequences: AUUCUUUGCUUCGCACUGG and UCUUUGCUUCGCACUGGUUCC.The present invention inhibits people circ_0001016 circular rna, and circ_0001016 circular rna in A549 and MBA-MD-231 cell can effectively be inhibited to express, it can be increased by, which combining with anti-tumor drug, inhibits it to grow and be proliferated, to effectively treat kinds of tumors.
Description
Technical field
The invention belongs to medical material technology and drug fields, specifically the present invention relates to a kind of circular rna s nucleotide,
More particularly, to people's circular rna s nucleotide.The nucleotide can be complementary with circ_0001016, to inhibit people circ_
0001016 expression, it plays antineoplastic action with other anti-tumor drugs.
Background technique
CircRNAs is the RNA that its universal molecule of one kind is in closed circular structure, can be by exon or introne, non-volume
The cyclisation such as code RNA are formed.ADAR1, QKI, FUS, HNRNPL and DHX9 etc. take part in the regulation of circRNAs forming process.
CircRNAs plays a role in several ways, research shows that circRNAs contain miRNA response element can be with competitive binding
MiRNA adjusts gene expression by influencing miRNA mode；Some circRNAs can interact with small nuclear ribonucleoprotein, adjust
Control the transcription of gene；The montage of the adjustable pre-mRNA of part circRNAs changes mRNA content, to influence protein
Yield.In the growth of cell, increment, differentiation, cycle regulating and multiple circRNAs in the process stress be waited to play an important role,
It is closely related with the generation, development and prognosis of the nervous system disease, diabetes, coronary heart disease and kinds cancer that it expresses variation.
RNA interferes (RNA interference, RNAi) technology to utilize, and double-strand tiny RNA is efficient, selective degradation is intracellular
Cognate rna is to silencing of target genes, to realize the function of interference target gene.
In recent years, although clinically the conjoint therapy of tumour is popularized, conjoint therapy survives to 5 years of tumor patient
Rate improves less, and middle and advanced stage survival is lower, and about 20%.Part chemotherapeutics side effect limits greatly the fortune of drug
With.Therefore, finding safer and more effective targeting conjoint therapy is the approach for improving tumor patient existence.
Summary of the invention
The purpose of the present invention is to provide one kind can inhibit specifical and efficiently circ_0001016 express siRNA and its
Using.
The object of the present invention is achieved like this, the sequence including synthesizing ribonucleotide by
18-23 continuous nucleotide sequence composition or complementary in AUUCUUUGCUUCGCACUGGUUCC (SEQ ID NO.1) sequence
18-23 continuous nucleotide sequence composition in sequence.Especially it includes sequences: AUUCUUUGCUUCGCACUGG (SEQ ID
) and UCUUUGCUUCGCACUGGUUCC (SEQ ID NO.3) NO.2.Nucleotide is ribonucleotide, deoxyribonucleotide
Or the chimera of ribonucleotide and deoxyribonucleotide.Nucleotide is further by ribose modification, base modification and phosphoric acid
The modification of one or more of backbone modification.Modification selected from fluoro modification, thio-modification, the modification of 2- methoxyl group, cholesterol modification,
One or more of LNA modification.Nucleotide and other antineoplaston drugs especially trivalent inorganic arsenic.Prepare treating cancer
Application in drug.Cancer include: liver cancer, lung cancer, cancer of pancreas, breast cancer, cervical carcinoma, colorectal cancer, gastric cancer, nasopharyngeal carcinoma, ovum
Nest cancer, carcinoma of prostate, chronic or acute leukemia, brain tumor, cancer of the esophagus, carcinoma of mouth, cardia cancer, colon cancer, gallbladder cancer, larynx
Cancer, gingival carcinoma, carcinoma of urethra, cutaneum carcinoma, the carcinoma of the rectum, cancer of middle ear, osteocarcinoma, carcinoma of testis, the cancer of endocrine system, lymphocyte
Property lymthoma.This project is supported by Yunnan Province with basic research program-general project 2017FB123.
(advantage) of the invention: the nucleotide of invention has good circ_0001016 inhibitory effect, acts on specificity
Target site, high specificity, toxicity is low, Small side effects and modification long half time, can share with a variety of anti-tumor drugs.
Specific embodiment
The present invention will be further described below with reference to the drawings, but the present invention is limited in any way, base
In present invention teach that it is made it is any transform or replace, all belong to the scope of protection of the present invention.
Specific embodiment:
Embodiment 1
Silencing RNA sequence in the present embodiment are as follows: AUUCUUUGCUUCGCACUGGdTdT (SEQ ID NO.2), and it is complementary
Sequence C CAGUGCGAAGCAAAGAAUdTdT (SEQ ID NO.4), all sequences are all that from 5 ends to 3 ends, wherein dTdT is
It has added up TT tail less than 19 nucleotide.The RNA sequence information of circ_0001016 is present in UCSC database.This project
It is supported by Yunnan Province with basic research program-general project 2017FB123.
Control synthesis
Firstly, synthesis includes the double-stranded RNA sequence of its complementary series by Shanghai JiMa pharmacy Technology Co., Ltd's synthesizing ribonucleotide
Column, control group are UUCUCCGAACGUGUCACGUdTdT (SEQ ID using the A06001 sequence of Ji Ma Pharmaceutical Technology Inc.
NO.5) and complementary
ACGUGACACGUUCGGAGAAdTdT (SEQ ID NO.6) is used as negative control.
Cell culture: A549 MBA-MD-231 cell is trained in 1640 culture mediums containing 10% fetal calf serum
It supports, fetal calf serum is purchased from cellmax company, and 1640 culture mediums are cultivated under the conditions of 5%CO2 from Hyclone in 37 DEG C.It receives
Collecting the good cell of growth conditions, centrifugation counts, and 200000, which are laid in 96 orifice plates, with 5000 every holes is inoculated in six orifice plates,
37 DEG C, 5%CO2 culture.
RNA transfection:
It using green skies company Lipo8000 transfection reagent, is operated according to operating instruction, A549 is transfected using six orifice plates
When, SIRNA amount is every hole 20ul, transfection reagent 15ul in six orifice plates, and culture medium 2ml, MBA-MD-231 use six holes
When plate transfects, SIRNA amount is every hole 10ul, transfection reagent 7.5ul, culture medium 2ml in six orifice plates, and detection in 96 hours is heavy
Silent effect, the result is shown in tables 1.
Table 1.circ_0001016 silencing efficiency
| Silencing efficiency | Control group | Silencing group 1 | Silencing group 1 |
| A549 | 1.02±0.07 | 0.24±0.04 | 0.26±0.05 |
| MBA-MD-231 | 1.04±0.09 | 0.15±0.05 | 0.18±0.06 |
Table 1 is the effect of SIRNA silencing of the present invention, and control group uses negative control segment, and silencing group 1 is heavy for embodiment 1
The result of silent nucleotide fragments；Silencing group 2 is 2 silent nucleotide segment of embodiment as a result, data use 2^- Δ Δ Ct table
Show.
96 orifice plate SIRNA amounts are every hole 0.5ul when A549 is transfected using 96 orifice plates, and transfection reagent is 0.5ul culture medium
For 0.1ml, 96 orifice plate SIRNA amounts are every hole 0.25ul when MBA-MD-231 is transfected using 96 orifice plates, and transfection reagent is
0.25ul culture medium is 0.1ml, and 30uM (every liter of micromole) is added in 24 hours addition sodium arsenite A549 after the two transfection,
MBA-MD-231 5uM, wherein a row is added without sodium arsenite, MTS detects cell viability after being further cultured for 48 hours, the result is shown in
Table 2.
Vigor (%) after addition arsenic after table 2.circ_0001016 silencing
| Vigor % | Not plus arsenic group | Control group | Experimental group 1 | Experimental group 2 |
| A549 | 100±4.53 | 83±3.52 | 68±3.45 | 71±2.31 |
| MBA-MD-231 | 101±5.62 | 84±3.77 | 61±2.56 | 65±4.01 |
Table 2 is the result table 2 of MTT of the present invention；Arsenic group is not added: being added without sodium arsenite, control group: to use negative control piece
The result of sodium arsenite is added after section, it is determined as 100%, arsenious acid is added after 1 embodiment of experimental group, 1 silent nucleotide segment silencing
Sodium as a result, after 2 embodiment of experimental group, 2 silent nucleotide segment silencing be added sodium arsenite result.
MTS detection uses 96 AQueous One Solution Cell of Promega company CellTiter
The method of Proliferation Assay, an specification carries out operation calculating.
Detect silencing efficiency use quantitative fluorescent PCR, the condition of PCR be 1,95 degree 2-10 divide, 2,95 degree 10 seconds, 3,60 degree
10 seconds, 4,72 degree 15 seconds, PCR reagent uses Roche or health for century, and primer sequence is as follows:
GGAACCAGTGCGAAGCAAAG (SEQ ID NO.7) and TTCCAAAATTGTGTCGACTCTTGT (SEQ ID NO.8) is used
2^ΔΔCtIndicate expression quantity.
Embodiment 2
RNA sequence in the present embodiment are as follows: UCUUUGCUUCGCACUGGUUCC (SEQ ID NO.3) and complementary series
GGAACCAGUGCGAAGCAAAGA(SEQ ID NO.9).The test methods such as cell culture and transfection are used only with embodiment 1
Silencing RNA sequence is different.Silencing efficiency, the result is shown in table 1, the result is shown in tables 2 by MTT.
SEQUENCE LISTING
<110>Kunming Medical University
<120>a kind of siRNA for inhibiting circ_0001016 expression and its application
<130>
<140>
<141>
<160> 9
<170> PatentIn version 3.3
<210> 1
<211> 23
<212> RNA
<213>artificial sequence
<400> 1
auucuuugcu ucgcacuggu ucc 23
<210> 2
<211> 19
<212> RNA
<213>artificial sequence
<400> 2
auucuuugcu ucgcacugg 19
<210> 3
<211> 21
<212> RNA
<213>artificial sequence
<400> 3
ucuuugcuuc gcacugguuc c 21
<210> 4
<211> 19
<212> RNA
<213>artificial sequence
<400> 4
ccagugcgaa gcaaagaau 19
<210> 5
<211> 19
<212> RNA
<213>artificial sequence
<400> 5
uucuccgaac gugucacgu 19
<210> 6
<211> 19
<212> RNA
<213>artificial sequence
<400> 6
acgugacacg uucggagaa 19
<210> 7
<211> 20
<212> DNA
<213>artificial sequence
<400> 7
ggaaccagtg cgaagcaaag 20
<210> 8
<211> 24
<212> DNA
<213>artificial sequence
<400> 8
ttccaaaatt gtgtcgactc ttgt 24
<210> 9
<211> 21
<212> RNA
<213>artificial sequence
<400> 9
ggaaccagug cgaagcaaag a 21
Claims (9)
1. it is a kind of inhibit circ_0001016 circular rna expression nucleotide, it is characterised in that: the sequence of the nucleotide by
18-23 continuous nucleotide sequence composition in AUUCUUUGCUUCGCACUGGUUCC sequence or complementary series.
2. nucleotide according to claim 1, it is characterised in that its sequence be AUUCUUUGCUUCGCACUGG or
UCUUUGCUUCGCACUGGUUCC and its complementary series.
3. nucleotide according to claim 2, it is characterised in that: the nucleotide is ribonucleotide, deoxyribose core
The chimera of thuja acid or ribonucleotide and deoxyribonucleotide.
4. nucleotide according to claim 2, it is characterised in that the nucleotide is further by ribose modification, base modification
With phosphoric acid backbone modification one or more of modification.
5. nucleotide according to claim 4, it is characterised in that the modification is selected from fluoro modification, thio-modification, 2- first
One or more of oxygroup modification, cholesterol modification, LNA modification.
6. a kind of pharmaceutical composition, it is characterised in that anti-swollen with other comprising the described in any item nucleotide of claim 1-5
Tumor therapeutic agent.
7. pharmaceutical composition according to claim 6, it is characterised in that other antineoplaston drugs are trivalent inorganic arsenic.
8. application of the pharmaceutical composition as claimed in claim 7 in preparation treating cancer drug.
9. application described in claim 8, wherein the cancer includes: liver cancer, lung cancer, cancer of pancreas, breast cancer, uterine neck
Cancer, colorectal cancer, gastric cancer, nasopharyngeal carcinoma, oophoroma, carcinoma of prostate, chronic or acute leukemia, brain tumor, cancer of the esophagus, oral cavity
Cancer, cardia cancer, colon cancer, gallbladder cancer, laryngocarcinoma, gingival carcinoma, carcinoma of urethra, cutaneum carcinoma, the carcinoma of the rectum, cancer of middle ear, osteocarcinoma, carcinoma of testis,
Cancer, the lymphocytic lymphoma of endocrine system.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910149634.6A CN109825504B (en) | 2019-02-28 | 2019-02-28 | siRNA for inhibiting circ _0001016 expression and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910149634.6A CN109825504B (en) | 2019-02-28 | 2019-02-28 | siRNA for inhibiting circ _0001016 expression and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109825504A true CN109825504A (en) | 2019-05-31 |
| CN109825504B CN109825504B (en) | 2022-06-17 |
Family
ID=66864827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910149634.6A Expired - Fee Related CN109825504B (en) | 2019-02-28 | 2019-02-28 | siRNA for inhibiting circ _0001016 expression and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109825504B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111218508A (en) * | 2020-03-18 | 2020-06-02 | 昆明医科大学 | Circular RNA as liver failure marker and application thereof |
| CN111394351A (en) * | 2020-03-18 | 2020-07-10 | 昆明医科大学 | siRNA for inhibiting DICER1-AS1 expression and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106591428A (en) * | 2016-09-23 | 2017-04-26 | 宁波大学 | Detection and application of new molecular marker hsa-circ-0001017 of gastric cancer |
-
2019
- 2019-02-28 CN CN201910149634.6A patent/CN109825504B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106591428A (en) * | 2016-09-23 | 2017-04-26 | 宁波大学 | Detection and application of new molecular marker hsa-circ-0001017 of gastric cancer |
Non-Patent Citations (4)
| Title |
|---|
| AMY Y WANG等: "The past,present,and future of CRM1/XPO1 inhibitors", 《STEM CELL INVESTIG》 * |
| DUDEKULA DB等: "CircInteractome: A web tool for exploring circular RNAs and their interacting proteins and microRNAs", 《RNA BIOLOGY》 * |
| GIOVANNI LUCA GRAVINA等: "Nucleo-cytoplasmic transport as a therapeutic target of cancer", 《J HEMATOL ONCOL》 * |
| IVANO LEGNINI等: "Circ-ZNF609 Is a Circular RNA that Can Be Translated and Functions in Myogenesis", 《MOLECULAR CELL》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111218508A (en) * | 2020-03-18 | 2020-06-02 | 昆明医科大学 | Circular RNA as liver failure marker and application thereof |
| CN111394351A (en) * | 2020-03-18 | 2020-07-10 | 昆明医科大学 | siRNA for inhibiting DICER1-AS1 expression and application thereof |
| CN111394351B (en) * | 2020-03-18 | 2023-11-07 | 济南爱新卓尔医学检验有限公司 | siRNA for inhibiting DICER1-AS1 expression and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109825504B (en) | 2022-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107454843B (en) | Pharmaceutical composition for treating cancer comprising microribonucleic acid as active ingredient | |
| CN111118011B (en) | siRNA for inhibiting expression of hsa _ circ _0027478 and application thereof | |
| CN109929841A (en) | It is a kind of inhibit circ_0006033 expression siRNA and its application | |
| CN111118012B (en) | siRNA for inhibiting expression of hsa _ circ _0051680 and application thereof | |
| EP2791337A1 (en) | Micrornas and uses therof | |
| CN102421899A (en) | Method for the treatment of acute myeloid leukemia | |
| CN109825504A (en) | It is a kind of inhibit circ_0001016 expression siRNA and its application | |
| CN109706152A (en) | It is a kind of inhibit circ_0001017 expression siRNA and its application | |
| CN109825502B (en) | siRNA for inhibiting circ _0054853 expression and application thereof | |
| CN109762822A (en) | It is a kind of inhibit circ_0002607 expression siRNA and its application | |
| CN111733158B (en) | siRNA for inhibiting expression of hsa _ circ _0003599 and application thereof | |
| Mahmoudian-Sani et al. | The role of microRNAs in human cancers | |
| CN103320444B (en) | For antisense oligonucleotide and the application of Microrna-21 Seed Sequences | |
| CN109825503B (en) | siRNA for inhibiting circ-0005050 expression and application thereof | |
| CN112494654B (en) | Pharmaceutical composition containing LncRNA HCG18 inhibitor and application thereof | |
| CN109825505A (en) | It is a kind of inhibit circ_0006493 expression siRNA and its application | |
| US8664191B2 (en) | Use of two microRNA moleculars in lung cancer prognosis and medicine preparation | |
| KR20220169178A (en) | Hairpin structure nucleic acid molecules capable of modulating target gene expression and uses thereof | |
| CN108642176B (en) | Application of PART1 as breast cancer diagnosis, treatment and prognosis marker | |
| CN101590243A (en) | Microrna treats and/or prevents application in the lymphoid tumor medicament in preparation | |
| CN111647598B (en) | siRNA for inhibiting expression of hsa _ circ _0027477 and application thereof | |
| CN111411155B (en) | Application of lncRNA IGFL2-AS1 AS colon cancer diagnosis marker | |
| KR101862247B1 (en) | Pharmaceutical Composition for Treating Cancer Comprising miRNA having Drug Response to serpinb5 and Application Thereof | |
| Madhura et al. | Altered expression of mirnas in tumorigenesis of oral squamous cell carcinoma-an overview | |
| CN111647597A (en) | siRNA for inhibiting expression of hsa _ circ _0027479 and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20220601 Address after: 230031 Room 408, building 65, Xingyuan community, No. 8, Kexue Avenue, Shushan District, Hefei City, Anhui Province Applicant after: Li Jiajia Address before: Kunming Medical University, 1168 Chunrong West Road, Chenggong District, Kunming, Yunnan 650500 Applicant before: KUNMING MEDICAL University |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20220617 |